Urological complications after COVID 19 vaccine according to age, sex and manufacturer.

Autor: Shim SR; Department of Biomedical Informatics, College of Medicine, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.; Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea., Kim KT; Department of Urology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea., Park E; Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea.; Department of Food and Nutrition, Kyungnam University College of Health Sciences, Changwon, Republic of Korea., Pyun JH; Department of Urology, Kangbuk Samsung Hospital, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Korea. docpjh79@hanmail.net., Kim JH; Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul, 04401, Republic of Korea. piacekjh@hanmail.net., Chung BI; Department of Urology, Stanford University Medical Center, Stanford, CA, USA.
Jazyk: angličtina
Zdroj: World journal of urology [World J Urol] 2023 Aug; Vol. 41 (8), pp. 2255-2263. Date of Electronic Publication: 2023 Jul 03.
DOI: 10.1007/s00345-023-04481-1
Abstrakt: Objectives: To examine the effects of age, sex, and type of COVID-19 vaccine on urological complications after vaccination with COVID-19.
Materials and Methods: We used the Vaccine Adverse Event Reporting System (VAERS) data from December 2020 to August 2022 to analyze urological symptoms post-vaccination adverse events (AEs) associated with COVID-19 vaccines authorized for the U.S.
Population: We collected AEs after 1-2 dose vaccination in VAERS, but not those after an additional booster shot. Age was divided into three groups (< 18 years, 18-64 years, and > 64 years), and compared incidence of AEs after vaccination with either mRNA vaccine (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) or a viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) as reported in VAERS data.
Results: Cumulative incidence rates (CIRs) of LUTS, voiding symptom, storage symptom, infection, and hematuria were 0.057, 0.282, 0.223, 1.245, and 0.214, respectively. By gender, CIRs OF LUTS, storage symptom, and infection were statistically significantly higher in women, whereas CIRs of voiding symptom and hematuria were statistically significantly higher in men. CIRs of AEs per 100,000 in age groups of < 18 years, 18-64 years, and > 64 years were 0.353, 1.403, and 4.067, respectively. All AE types except for voiding symptom displayed the highest CIRs in the Moderna vaccine group.
Conclusions: Based on an updated analysis of available data, the prevalence of urologic complications following administration of COVID-19 vaccines is low. However, specific urologic complications such as gross hematuria are not low in incidence.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: